Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a migraine pill taken daily or every other day stop attacks before they start?

NCT ID NCT05217927

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 4 trial tested the drug rimegepant as a preventive treatment for people with episodic migraines (4–14 migraine days per month). Over 1,400 participants were randomly assigned to take rimegepant daily, every other day, or a placebo for 12 weeks. The main goal was to see how much each dosing schedule reduced the number of migraine days per month compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rimegepant
What this could lead to
If successful, this could offer a new, flexible dosing option for preventing episodic migraines, potentially reducing migraine frequency.
What could go wrong
This is a completed Phase 4 study, but results are not yet published. The benefit over placebo may be modest, and not all participants may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

1,415 people

The number who actually took part.

Started

Mar 2022

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\) Target Population: Subject has at least 1 year history of episodic migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following: 1. Age of onset of migraines prior to 50 years of age 2. Migraine attacks, on average, lasting 4-72 hours if untreated 3. Per subject report, 4-14 migraine attacks per month within the last 3 months prior to the Screening Visit (month is defined as 4 weeks for the purpose of this protocol Exclusion Criteria: 1. Sex and Reproductive Status: 1. WOCBP who are unwilling or unable to use an acceptable contraceptive method or abstinence to avoid pregnancy for the entire study and for 60 days after the last dose of study drug 2. Women who are pregnant or breastfeeding 3. Women with a positive pregnancy test at screening or prior to study drug administration 2. Prohibited Medications: 1. Use of prophylactic migraine medication within 30 days prior to the Screening Visit. 2. History of use of analgesics (e.g., non-steroidal anti-inflammatory drugs \[NSAIDs\] or acetaminophen) on ≥ 15 days per month during the 3 months (12 weeks) prior to the Screening Visit. 3. Use of medication accepted for treatment of acute migraine for a nonmigraine indication on ≥ 15 days per month during the 3 months (12 weeks) prior to the Screening Visit. 4. Subjects who previously discontinued biologic migraine medication must have done so at least 6 months (24 weeks) prior to the Screening Visit. 5. Subjects taking a prohibited medication as defined per protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine

Contacts and locations

Locations

  • AMR Clinical

    Tempe, Arizona, 85281, United States

  • APD Clinical Research

    Magnolia, Texas, 77355, United States

  • ASST Spedali Civili di Brescia, U.O. Neurologia

    Brescia, 25123, Italy

  • Aggarwal and Associates Limited

    Brampton, Ontario, L6T 0G1, Canada

  • Alliance for Multispecialty Research, LLC

    Las Vegas, Nevada, 89119, United States

  • AppleMed Research Group, LLC

    Miami, Florida, 33126, United States

  • Arztepartnerschaft Dr. med. J. Springub/ W. Schwarz -Studienzentrum Nord-West

    Westerstede, Lower Saxony, 26655, Germany

  • Axiom Research, Llc

    Colton, California, 92324, United States

  • Azienda Ospedaliero Universitaria di Careggi - Cliniche Mediche

    Florence, Tuscany, 50134, Italy

  • Bluewater Clinical Research Group Inc.

    Sarnia, Ontario, N7T 4X3, Canada

  • CPS Research

    Glasgow, Scotland, G20 7BE, United Kingdom

  • CTC Clinical Trial Consultants AB

    Stockholm, Stockholms LÄN [se-01], 171 64, Sweden

  • Calgary Headache & Assessment Management Program (CHAMP)

    Calgary, Alberta, T3M 1M4, Canada

  • California Neuroscience Research Medical Group, inc.

    Sherman Oaks, California, 91403, United States

  • Centricity Research

    Halifax, Nova Scotia, B3S 1N2, Canada

  • Centrum Medyczne Pratia Bydgoszcz

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Centrum Medyczne Pratia Czestochowa

    Częstochowa, Silesian Voivodeship, 42-200, Poland

  • Centrum Medyczne Pratia Katowice

    Katowice, Silesian Voivodeship, 40-081, Poland

  • Christian-Doppler-Klinik

    Salzburg, 5020, Austria

  • Clinical Investigation Specialists, Inc.

    Gurnee, Illinois, 60031, United States

  • Clinical Research Associates, Inc.

    Nashville, Tennessee, 37203, United States

  • Clinical Research Institute

    Los Angeles, California, 90048, United States

  • Clinvest Research, LLC

    Springfield, Missouri, 65807, United States

  • Collective Medical Research

    Overland Park, Kansas, 66210, United States

  • Datamed GmbH

    Cologne, 50935, Germany

  • Dent Neurosciences Research Center, Inc.

    Amherst, New York, 14226, United States

  • Diex Recherche Sherbrooke Inc.

    Sherbrooke, Quebec, J1L 0H8, Canada

  • Fondazione Mondino - Istituto Neurologico Nazionale IRCCS

    Pavia, Padua, 27100, Italy

  • FutureSearch Trials of Dallas, LP

    Dallas, Texas, 75231, United States

  • FutureSearch Trials of Neurology

    Austin, Texas, 78731, United States

  • Hometown Urgent Care and Research

    Huber Heights, Ohio, 45424, United States

  • Hopital Gabriel Montpied

    Clermont-Ferrand, 63003, France

  • Hopital de La Timone

    Marseille, 13385, France

  • Hospital Alvaro Cunqueiro

    Vigo, Pontevedra, 36312, Spain

  • Hospital Clinico Universitario de Valladolid • HCUV

    Valladolid, Castille and León, 47003, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario y Politecnico La Fe

    Valencia, 46026, Spain

  • IRCCS Istituto delle Scienze Neurologiche Bologna, Unità Operativa di Neurologia - Ospedale Bellaria

    Bologna, 40139, Italy

  • IRCCS San Raffaele Roma

    Rome, 00197, Italy

  • Indywidualna Praktyka Lekarska Dr Hab. Med. Anna Szczepanska-Szerej

    Lublin, Lublin Voivodeship, 20-582, Poland

  • Instituto de Investigaciones del Sueno

    Madrid, 28036, Spain

  • Istituto Neurologico "Carlo Besta" Fondazione IRCCS

    Milan, 20133, Italy

  • James K. Lai MD Inc.

    Vancouver, British Columbia, V5Z 1K3, Canada

  • Klinische Forschung Dresden GmbH

    Dresden, Saxony, 01069, Germany

  • Klinische Forschung Hamburg GmbH

    Hamburg, 20253, Germany

  • Klinische Forschung Karlsruhe GmbH

    Karlsruhe, Baden-Wurttemberg, 76137, Germany

  • Klinische Forschung Schwerin GmbH

    Schwerin, Mecklenburg-Vorpommern, 19055, Germany

  • Kopfschmerzzentrum Frankfurt

    Frankfurt, 65929, Germany

  • Krakowska Akademia Neurologii Sp. Z o.o.

    Krakow, Lesser Poland Voivodeship, 31-505, Poland

  • Ladulaas Clinical Trials

    Borås, SE 506 30, Sweden

  • Lakeside Healthcare Research

    Corby, Northamptonshire, NN17 2UR, United Kingdom

  • MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak

    Wroclaw, Lower Silesian Voivodeship, 52-210, Poland

  • MTZ Clinical Research Powered by Pratia

    Warsaw, 02-172, Poland

  • Manna Research (Toronto)

    Toronto, Ontario, M9W 4L6, Canada

  • Manna Research Inc. (Burlington North)

    Burlington, Ontario, L7M 4Y1, Canada

  • MediSphere Medical Research Center, LLC

    Evansville, Indiana, 47714, United States

  • Medizinische Universitat Innsbruck

    Innsbruck, Tyrol, 6020, Austria

  • Milestone Research Inc.

    London, Ontario, N5W 6A2, Canada

  • Mirtorabi Medicine Professional Corporation

    Stouffville, Ontario, L4A 1H2, Canada

  • Montefiore Medical Center

    The Bronx, New York, 10461, United States

  • NZOZ Neuromed M. i M. Nastaj Sp. P.

    Lublin, 20-064, Poland

  • NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS

    Katowice, Silesian Voivodeship, 40-123, Poland

  • Neurologia Slaska Centrum Medyczne

    Katowice, Silesian Voivodeship, 40-689, Poland

  • Neurologisch-verhaltensmedizinische Schmerzklinik Kiel

    Kiel, 24194, Germany

  • Neurology Offices of South Florida, PLLC

    Boca Raton, Florida, 33428, United States

  • Neurology Service: Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, 39008, Spain

  • Neurorehabilitation Unit-ICOT Istituto Marco Pasquali

    Latina, 04100, Italy

  • Next Stage Sp. Z o.o.

    Warsaw, Masovian Voivodeship, 02-121, Poland

  • OCT Research ULC

    Kelowna, British Columbia, V1Y 1Z9, Canada

  • Ospedale Sant Andrea - Facolta Medicina Psicologia - Universita degli Studi di Roma Sapienza

    Rome, Lazio, 00189, Italy

  • Panthera Bio Partners

    Preston, Lancashire, PR2 9QB, United Kingdom

  • Panthera Biopartners

    Rochdale, Great Manchester, O11 4AU, United Kingdom

  • Panthera Biopartners - Enfield

    London, EN3 4GS, United Kingdom

  • Panthera Biopartners - Sheffield

    Sheffield, South Yorkshire, S2 5FX, United Kingdom

  • Panthera Biopartners Glasgow

    Glasgow, G51 4TY, United Kingdom

  • Pharmasite

    Malmö, Skåne County, 21152, Sweden

  • Pratia MCM Krakow

    Krakow, Lesser Poland Voivodeship, 30-510, Poland

  • Preferred Primary Care Physicians, Inc.

    Pittsburgh, Pennsylvania, 15236, United States

  • ProbarE i Lund

    Lund, 222 22, Sweden

  • ProbarE i Stockholm AB

    Stockholm, 113 29, Sweden

  • Re-Cognition Health

    Guildford, Surrey, GU2 7YD, United Kingdom

  • Re-Cognition Health

    Birmingham, WEST Midlands, B16 8LT, United Kingdom

  • Re-Cognition Health - Bristol

    Bristol, South WEST, BS32 4SY, United Kingdom

  • Re:Cognition Health - London

    London, Marylebone, W1G 9JF, United Kingdom

  • Re:Cognition Health - Winchester

    Winchester, Hampshire, SO21 1HU, United Kingdom

  • Re:Cognition Health-Private Practice

    London, Marylebone, W1G9RU, United Kingdom

  • Royal Primary Care Ashgate, Chesterfield Royal Hospital, NHS Foundation Trust

    Chesterfield, Derbyshire, S40 4AA, United Kingdom

  • Seattle Clinical Research Center

    Seattle, Washington, 98105, United States

  • Siteworks - Zentrum fur klinische Studien Hannover

    Hanover, Lower Saxony, 30449, Germany

  • Solumed Centrum Medyczne

    Poznan, Greater Poland Voivodeship, 60-529, Poland

  • Studieenheten Akademiskt Specialistcentrum SLSO

    Stockholm, 11361, Sweden

  • Studienzentrum Dr. A Schwittay

    Böhlen, 04564, Germany

  • Texas Center for Drug Development, Inc.

    Houston, Texas, 77081, United States

  • Toronto Memory Program

    Toronto, Ontario, M3B 2S7, Canada

  • Tribe Clinical Research LLC

    Greenville, South Carolina, 29607, United States

  • Universitatsklinikum Jena

    Jena, Thuringia, 07747, Germany

  • Upstate Clinical Research Associates, LLC

    Williamsville, New York, 14221, United States

  • Velocity Clinical Research - Columbia

    Columbia, South Carolina, 29204, United States

  • Velocity Clinical Research - Providence

    East Greenwich, Rhode Island, 02818, United States

  • Velocity Clinical Research, Gaffney

    Gaffney, South Carolina, 29340, United States

  • Velocity Clinical Research, Medford

    Medford, Oregon, 97504, United States

  • Virgen del Rocio Hospital

    Seville, 41013, Spain

  • Vitos Orthopaedische Klinik Kassel

    Kassel, Hesse, 34131, Germany

  • Wasatch Clinical Research , LLC(Administrative Location)

    Salt Lake City, Utah, 84107, United States

  • Wellnow Urgent Care and Research

    Columbus, Ohio, 43228, United States

  • Wojskowy Instytut Medyczny

    Warsaw, Masovian Voivodeship, 04-141, Poland

  • Wr-Pri, Llc

    Newport Beach, California, 92660, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.